It is an exciting time in the world of parathyroid research, particularly in regard to new treatments for patients with hypoparathyroidism and we don't want Australian patients to miss out! On this page we will be publishing key research as well as details of any clinical trials in which patients may participate.
Yorvipath
Yorvipath is a hormone replacement medicine for treating adults with chronic hypoparathyroidism.
In patients with this condition, the parathyroid glands in the neck do not produce enough parathyroid hormone (PTH) which controls the level of calcium in the blood. As a result, patients have low levels of calcium and may experience problems with bones, muscles, the heart, kidneys and other parts of the body.
Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020. Further information on the orphan designation can be found on the EMA website.
Yorvipath contains the active substance palopegteriparatide.
Read more here
Yorvipath is a hormone replacement medicine for treating adults with chronic hypoparathyroidism.
In patients with this condition, the parathyroid glands in the neck do not produce enough parathyroid hormone (PTH) which controls the level of calcium in the blood. As a result, patients have low levels of calcium and may experience problems with bones, muscles, the heart, kidneys and other parts of the body.
Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020. Further information on the orphan designation can be found on the EMA website.
Yorvipath contains the active substance palopegteriparatide.
Read more here